{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-048507","form_type":"8-K","ticker":"IXHL","cik":"0001873875","company_name":"Incannex Healthcare Inc.","filed_at":"2025-05-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.323625+00:00","generated_at":"2026-05-20T06:37:22.534925+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Incannex Healthcare advances IHL-42X RePOSA trial to Phase 3 after FDA clearance","bullets":["FDA cleared Phase 3 protocol for IHL-42X under IND; trial for obstructive sleep apnea (OSA) with no approved oral therapy.","Phase 3 will be US-only, leveraging Phase 2 infrastructure; ~20 existing sites roll over, 10 new sites added.","Study design: randomized, placebo-controlled, 12 months, including head-to-head against monotherapy components.","Primary endpoint: change in Apnea-Hypopnea Index (AHI); top-line Phase 2 results due in coming weeks.","CEO cites potential to become first FDA-approved oral therapy for OSA; commercial discussions underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-048507","json":"https://secwatch.observer/filing/0001213900-25-048507.json","markdown":"https://secwatch.observer/filing/0001213900-25-048507.md","text":"https://secwatch.observer/filing/0001213900-25-048507.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025048507/0001213900-25-048507-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025048507/ea0243466-8k_incannex.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T06:37:22.534925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}